Study Shows Anti-Obesity Drugs May Reduce Mortality in Covid-19
Related media - Latest news
Recent research has highlighted a potentially game-changing secondary benefit of Wegovy, an established obesity management drug. In a large clinical trial, individuals taking Wegovy were observed to have a significantly reduced death rate from Covid-19 compared to those not taking the drug.
Clinical Trial Insights
The study participants, who were already using Wegovy for obesity, contracted Covid-19 at the usual rate expected in the general population. However, their risk of succumbing to the virus was reduced by a third. This remarkable reduction in mortality was surprising and suggests an indirect benefit of the drug that had not previously been recognized.
Wider health implications
In addition to COVID-19 mortality, the study also documen...